Edition:
United States

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.27USD
4:00pm EDT
Change (% chg)

$0.01 (+0.23%)
Prev Close
$4.26
Open
$4.24
Day's High
$4.29
Day's Low
$4.04
Volume
29,003
Avg. Vol
103,430
52-wk High
$7.24
52-wk Low
$2.86

Chart for

About

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $233.73
Shares Outstanding(Mil.): 54.87
Dividend: --
Yield (%): --

Financials

  CDXC.OQ Industry Sector
P/E (TTM): -- 213.33 32.89
EPS (TTM): -0.45 -- --
ROI: -80.36 -3.69 13.14
ROE: -82.70 -5.73 15.15

BRIEF-Chromadex Q1 Loss Per Share $0.15

* Q1 SALES ROSE 95 PERCENT TO $6.6 MILLION Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer

* CHROMADEX APPOINTS FRANK JAKSCH AS EXECUTIVE CHAIRMAN, ROB FRIED AS CHIEF EXECUTIVE OFFICER AND KURT GUSTAFSON AS LEAD DIRECTOR

Apr 23 2018

BRIEF-Chromadex Corporation Q4 Loss Per Share $0.17

* Q4 REPORTED LOSS FROM CONTINUING OPERATIONS NEGATIVELY IMPACTED BY NON-CASH CHARGE OF $3.4 MILLION RELATED TO STOCK-BASED COMPENSATION

Mar 08 2018

BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board

* CHROMADEX CHAIRMAN STEPHEN ALLEN WILL RETIRE FROM BOARD OF DIRECTORS

Feb 16 2018

BRIEF-ChromaDex Corp Sees Q4 2017 Revenue About $7.5 Mln

* AN OPERATING LOSS FOR Q4 OF 2017 IS EXPECTED TO BE IN A RANGE OF $8.5 MILLION TO $9.5 MILLION

Feb 12 2018

BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent

* CHROMADEX - PATENT TRIAL AND APPEAL BOARD OF U.S. PATENT AND TRADEMARK OFFICE DENIED ELYSIUM HEALTH INC.'S REQUEST TO INVALIDATE U.S. PATENT

Jan 22 2018

Earnings vs. Estimates